PRESS RELEASE
News
-
-
-
-
-
-
PRESS RELEASE
THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)
THX Pharma and BBDF announce European patent grant for Batten-1 treatment of juvenile Batten disease, ensuring long-term exclusivity through 2041 -
PRESS RELEASE
THX Pharma et la Beyond Batten Disease Foundation annoncent la délivrance d'un brevet européen protégeant l'utilisation de Batten-1 dans la maladie de Batten juvénile (CLN3)
THX Pharma et la Beyond Batten Disease Foundation annoncent la délivrance du brevet européen protégeant l'utilisation du miglustat dans le traitement de la maladie de Batten juvénile jusqu'en 2041 -
-
-
PRESS RELEASE
THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3)
THX Pharma, BBDF, and Biocodex submit regulatory applications for Phase 3 trial of Batten-1, a treatment for juvenile Batten disease. Trial aims to evaluate efficacy in pediatric patients
